Clinical trials: Hematologic Disease and Disorders
Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia.
- Conditions
- Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
- Trial name
- NCT04502394
- Testing
- KRT-232, acalabrutinib
- Where
- 45 sites in United States, Australia and 9 more
- Volunteers
- 84 people
- Sponsor
- Kartos Therapeutics, Inc.
Multiple Myeloma
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease.
- Trial name
- NCT03110822
- Testing
- Ruxolitinib Oral Tablet [Jakafi], Lenalidomide, Methylprednisolone
- Where
- 13 sites in United States
- Volunteers
- 134 people
- Sponsor
- Oncotherapeutics
Paroxysmal Nocturnal Hemoglobinuria (PNH)
SLN12140 in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China
The goal of this clinical trial is to learn if drug SLN12140 works to treat Complement Inhibitor-Naïve Subjects with Paroxysmal Nocturnal Hemoglobinuria in adults.
- Trial name
- NCT07387302
- Testing
- SLN12140
- Volunteers
- 10 people
- Sponsor
- Linno Pharmaceuticals, Inc.
Paroxysmal Nocturnal Hemoglobinuria (PNH)
A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH
This study will be the initial exploration of pegcetacoplan in patients with PNH. The assessments of the safety, tolerability, PK, and PD following administration of single and multiples doses of pegcetacoplan will guide…
- Trial name
- NCT02264639
- Testing
- Pegcetacoplan
- Where
- 7 sites in United States
- Volunteers
- 9 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Anaemia
Absorption and Elimination of Radiolabeled Daprodustat
Absorption, metabolism and excretion of daprodustat (GSK1278863) have been studied in previous clinical trials; however, the elimination routes and metabolic pathways of daprodustat have not been fully elucidated in humans.
- Trial name
- NCT03239522
- Testing
- [14C]-GSK1278863 solution for IV infusion, [14C]-GSK1278863 oral solution, Daprodustat 6 mg oral tablet
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Primary Objectives: To evaluate the safety and tolerability of isatuximab administered subcutaneously (SC) versus intravenously (IV) To assess the safety and tolerability (including local injection site tolerability) of…
- Trial name
- NCT04045795
- Testing
- isatuximab SAR650984 IV, pomalidomide, dexamethasone
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 56 people
- Sponsor
- Sanofi
Multiple Myeloma
Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
The purpose of this Phase II study is to evaluate the safety and effectiveness (good and bad effects) of carfilzomib given as a 30-minute infusion and at a dose of 70 mg/m2 to treat patients with multiple myeloma (MM), who are…
- Trial name
- NCT02294357
- Testing
- Carfilzomib, Dexamethasone, Prednisone
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- Oncotherapeutics
Myelofibrosis
Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 Tablets
Primary objective: To evaluate the effect of rabeprazole on the primary pharmacokinetics of TQ05105 tablets. Secondary objective: To assess the safety and tolerability of single oral administration of TQ05105 tablets alone and in…
- Trial name
- NCT07608666
- Testing
- TQ05105 tablets, Rabeprazole sodium enteric-coated tablets
- Where
- China
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Venous Thromboembolism
Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE)
The purpose of this study is to validate the Ottawa score (risk of thromboembolic recurrences) in cancer patients with thromboembolic disease treated with tinzaparin (Innohep®)
- Trial name
- PREDICARE (NCT03099031)
- Testing
- Tinzaparin
- Where
- France
- Volunteers
- 420 people
- Sponsor
- LEO Pharma
Primary Immune Thrombocytopenia
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
This is a Phase 2, open-label, multicenter, multiple subcutaneous injection, safety and efficacy study of PF-06835375 in adult participants with primary immune thrombocytopenia (ITP).
- Trial name
- NCT05070845
- Testing
- PF-06835375
- Where
- 24 sites in United States, Australia and 5 more
- Volunteers
- 61 people
- Sponsor
- Pfizer
Multiple Myeloma
Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple Myeloma
The purpose of this individual-patient investigational new drug (IND) single patient request (SPR) is to provide participants treatment with JNJ-68284528, an investigational product prior to its marketing authorization.
- Trial name
- NCT04452994
- Testing
- JNJ-68284528
- Sponsor
- Janssen Research & Development, LLC
Leukemia, Myeloid, Acute
HDM201 Added to CT in R/R or Newly Diagnosed AML
This is a multi-center open-label Phase I/II study investigating orally administered HDM201 in combination with chemotherapy in two populations: subjects with first line AML or subjects with relapsed/refractory AML.
- Trial name
- NCT03760445
- Testing
- HDM201, cytarabine, anthracycline
- Sponsor
- Novartis Pharmaceuticals
Lymphoma, Multiple Myeloma
Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry on a Cohort of Patients Receiving Plerixafor
In the European Union (EU), plerixafor is indicated in combination with granulocyte colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells (HSCs) to the peripheral blood (PB) for collection and…
- Trial name
- NCT01362972
- Volunteers
- 7,801 people
- Sponsor
- Genzyme, a Sanofi Company
Anemia, Chronic Kidney Disease
Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis
BCD-131 is pegylated darbepoetin beta. This clinical study BCD-131-3 is a randomized, open-label, phase III study of the efficacy and safety of BCD-131 and Mircera used for the treatment of anemia in end-stage chronic kidney…
- Conditions
- Anemia, Chronic Kidney Disease, Chronic Kidney Disease Patients on Hemodialysis, Chronic Kidney Disease 5D
- Trial name
- NCT07119372
- Testing
- BCD-131 (pegdarbepoetin beta), Mircera (methoxypolyethylene glycol-epoetin beta)
- Where
- 14 sites in Russia
- Volunteers
- 228 people
- Sponsor
- Biocad
Multiple Myeloma
Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.
This study will evaluate the safety of LBH589 given in combination with lenalidomide and dexamethasone in adult patients with multiple myeloma
- Trial name
- NCT00532675
- Testing
- LBH589, Lenalidomide
- Where
- 10 sites in United States, Australia and 2 more
- Volunteers
- 46 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myelogenous Leukemia
Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)
The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experienced by patients that receive AZD4877 on a daily times 3 schedule in…
- Trial name
- NCT00486265
- Testing
- AZD4877
- Where
- 4 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- AstraZeneca
Acute Myeloid Leukemia, Myelodysplastic Syndromes
A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies
This study will be divided into two parts, Parts A and B and will enroll patients with relapsed/refractory AML or MDS/chronic myelomonocytic leukemia (CMML) patients who have failed up to 2 prior therapeutic regimens.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
- Trial name
- NCT04937166
- Testing
- DSP107, Azacitidine, Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Kahr Medical
Sepsis and Coagulopathy
The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy
The purpose of the study is to evaluate if ART-123 given to patients who have severe sepsis can decrease mortality.
- Trial name
- Scarlet2 (NCT03517501)
- Testing
- ART-123
- Sponsor
- Asahi Kasei Pharma America Corporation
Multiple Myeloma
A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma
The purpose of this study is to evaluate the safety and tolerability and to establish the maximum tolerated dose of JNJ-26481585 combined with VELCADE and dexamethasone.
- Trial name
- NCT01464112
- Testing
- JNJ-2641585 / VELCADE / Dexamethasone
- Where
- 3 sites in France
- Volunteers
- 18 people
- Sponsor
- Janssen Research & Development, LLC
Anemia
SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies
The purpose of this study is to evaluate the safety and efficacy of SAL-0951 in the treatment of chemotherapy-induced anemia (CIA) in patients with non-myeloid malignancies
- Trial name
- NCT06737081
- Testing
- SAL-0951 tablets 4mg, SAL-0951 tablets 5mg
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.